Tweets
#RWCS24 @JointMD @RWCSmtg review the TNFi differences molecularly. @RheumNow https://t.co/6JAnNwwV0n
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
"In solid tumors, treat your RA patient as if they do not have a cancer, meaning do not change your therapy if the patient is responding well. Things may get dicey if hematologic malignancy." @RheumNow #RWCS24
I work w/ my onc team to ensure the patient has the needed support.
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
Anticardiolipin ab are the most frequent aPL in SLE. Dr. M. Petri #RWCS24 @RWCSmtg @RheumNow https://t.co/cCxhctLTGf
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
Dr. Petri reviews the 2023 ACR/APS Classification Criteria at #RWCS24 @RheumNow @RWCSmtg https://t.co/FWGsFk02Dn
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
Steroids are associated with MACE events in RA. #RWCS24 @RheumNow @RWCSmtg https://t.co/U6ssALNspe
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
Controversial MOSAIC results. @JointMD and @RWCSmtg discuss nuances listed below. #RWCS24 @RheumNow https://t.co/aVRJpqHuUM
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
Who do you watch closely for developing RA? @RheumNow and @RWCSmtg suggest additional risk factors for ratcheting closer to RA. #RWCS24 https://t.co/lV3I5emn72
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
Obese patients more likely to have a lower DMARD response compared to under/normal weighted patients. This still needs to be evaluated on a personal patient level, however, this is an important, layered discussion to have. #RWCS24 @RWCSmtg @rheumnow https://t.co/KIkVXQdcPm
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 4 months ago
Oral IL-23 Inhibitor Effective in Psoriasis
The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
https://t.co/9GjR6Vx3At https://t.co/tZiykNuzKS
Dr. John Cush @RheumNow ( View Tweet )
2 years 4 months ago
Mayo study of 1643 #RA pts (Dzduration 7 yrs) found 4 clusters based on # of comorbidities (Cluster 1 [42%] few comorbidities & cluster 4 [7%] > 10). Cluster 1 w/ good prog/survival; but cluster 4 was older, less DMARDs/biologics https://t.co/qAWZoXVWlv https://t.co/g3gMsNj848
Dr. John Cush @RheumNow ( View Tweet )
2 years 4 months ago
Retrospective cohort analysis of 330 psoriasis pts - 83 (25%) developed #PsA after mean of 36 (3.5–114) mos. PsA Predictive factors include being female (OR=3.33), nails involved (OR=5.4), severe PSO (OR=27.4), po systemic Rx prior to PsA (4.1) https://t.co/Hpn6f1EUfD https://t.co/QanJkNi5S6
Dr. John Cush @RheumNow ( View Tweet )
2 years 4 months ago
Sex Disparities in PsA/SpA
https://t.co/3pmFyo6Ztm https://t.co/zanPiI7GT5
Dr. John Cush @RheumNow ( View Tweet )
2 years 4 months ago
